StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) shareholders

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.82−0.09 (-9.43%)

Close on Nov 13, 2026Market cap $2.41MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.5%
0M of 3M shares
Institutional holders
3
2 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Soo Kow Lai
Joint filing with Kim Hai Wong (5.90%), Liong Tai Tan (5.86%) and 2 more
1,250,0017.03%13D (active)Dec 11, 2023
Fidelion Diagnostics Pte. Ltd.
Joint filing with Molecule Bio LLC (13.40%), Xiao Ling (13.40%) and 1 more
392,32913.40%13G (passive)Nov 28, 2025
Tan Lee Su-Leng338,70911.50%13D (active)Aug 13, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of BGLCValueChange% of portfolio
Hrt Financial LP14,2830.49%$27.00KNew0.00%
UBS Group AG1010.00%$197−1300.00%
Caitong International Asset Management Co., Ltd10.00%$2New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202630M0.5%2 / 01 / 10M0M
Q1 202620M0.0%2 / 00 / 10M0M
Q4 202510M1.6%0 / 10 / 10M0M
Q3 202520M0.8%1 / 01 / 00M0M
Q2 202510M0.3%1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

2 funds held BGLC in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of BGLCValue% of fundAs of
Fidelity Nasdaq Composite Index Fund2,3680.08%$5.49K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund30.00%$60.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Lee Su-Leng TanChief Executive Officer, Director, 10% owner338,70911.55%Aug 14, 2026
Set Fui ChongChief Financial Officer96,7743.30%Aug 14, 2026
Jook Yuen LowDirector17,3900.59%Aug 14, 2026
Abdul Hamid Muhammad Azrul BinDirector32,2581.10%Aug 14, 2026
Chee Keong YapDirector32,2581.10%Aug 14, 2026
Diagnostics Pte. Ltd. Fidelion–392,32913.37%Aug 7, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Set Fui Chong
Chief Financial Officer
Aug 13, 2026Award+96,774––96,774
Jook Yuen Low
Director
Aug 13, 2026Award+16,129––17,390
Abdul Hamid Muhammad Azrul Bin
Director
Aug 13, 2026Award+32,258––32,258
Lee Su-Leng Tan
Chief Executive Officer, Director, 10% owner
Aug 13, 2026Award+338,709––338,709
Chee Keong Yap
Director
Aug 13, 2026Award+32,258––32,258

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.16%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-64.9%
From 0M shares
Short volume, 20 days
49.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioNexus Gene Lab's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,115 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?